Bayer Animal Health and Paraco agree on access to lead molecules
Bayer Animal Health GmbH and Paraco Technology Limited, a 100% owned subsidiary of AgResearch, New Zealand’s largest Crown Research Institute, announced they have signed an option agreement allowing Bayer exclusive access to Paraco’s current lead molecules for testing and development in animal health. The focus in the foreseen activities lies in the research of parasiticides.
Dr Peggy Dillender, Global Head of acquisitions and licensing at Bayer Animal Health, said that Bayer were pleased to sign the agreement with Paraco and to tap into some of the innovative animal health research being conducted in New Zealand. “We hope this will be the beginning of a long and fruitful relationship between Bayer, Paraco and indirectly AgResearch,” said Dr Dillender.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Siegfried (USA) Inc. and Jazz Pharmaceuticals sign Supply Agreement
Amyloid formation may link Alzheimer disease and type 2 diabetes
BioFocus and InterMed Discovery Announce Marketing Collaboration
Biocrea announces novel treatment opportunities for CNS diseases - Company has filed US patent on novel, brain-penetrating PDE2 and PDE10 inhibitors

Discovery of a potential new therapy for inflammatory arthritis - Researchers at the Schroeder Arthritis Institute in Toronto have made a discovery that could lead to new treatments for axial spondyloarthritis.

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases
Deuterium Depletion: A New Concept in Anticancer Drug Development

So-called junk DNA plays critical role in mammalian development - Knocking out transposon promoter leads to pup death in mice; similar promoters found in many mammals
Leprosy strain genotyped from medieval pilgrim at UK burial site - Medieval leprosy victim in UK cemetery was likely a religious pilgrim, possibly from overseas
Biological wires carry electricity thanks to special amino acids
